Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access

Core Insights - Femasys Inc. has announced that its FemBloc permanent birth control system has achieved MDSAP certification, which will facilitate regulatory and commercial execution in key global markets [1][2] - The MDSAP certification enhances the company's manufacturing credibility and operational scalability, supporting ongoing commercialization in Europe and enabling market entry in additional high-value regions [1][2] Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally through a patent-protected portfolio of products [3] - The company is actively commercializing its lead product innovations in the U.S. and key international markets, including a fertility portfolio that features FemaSeed, FemSperm, and FemVue [3] Product Details - FemBloc is a non-surgical solution for permanent birth control that addresses the unmet need in women's reproductive health by using a patented delivery system to create natural scar tissue for permanent occlusion [2][4] - The product has received full regulatory approval in Europe, the UK, and New Zealand, and its commercialization will be completed through strategic partnerships in select European countries [4]